Please assess the completion status of the following clinical trial:

Trial Title: Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed squamous cell carcinoma (SCC) of the upper aerodigestive tract~* Recurrent disease or second primary SCC~  * Recurrence or second primary must be confined to the head and neck above the clavicles (loco-regional recurrence)~ * Majority (≥ 75%) of the recurrent tumor must be in areas previously irradiated to ≥ 45 Gy~ * More than one recurrence allowed provided the first recurrence occurred \> 6 months after the completion of prior radiotherapy~* Unresectable disease OR has high-risk features after resection (e.g., positive margins and/or extracapsular extension)~  * No signs of carotid exposure~* No primary nasopharyngeal or salivary gland tumor~* Equivocal pulmonary nodes on chest CT scan allowed provided they are \< 1 cm, cannot be safely biopsied, or are negative on PET scan~* No distant metastasis~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* ANC ≥ 2,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 8.0 g/dL (transfusion or other intervention allowed)~* Bilirubin \< 1.5 mg/dL~* AST or ALT \< 2 times upper limit of normal~* Creatinine clearance ≥ 50 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to submit prior radiotherapy records to assure that the spinal cord tolerance is not exceeded~* No active cardiac disease, including any of the following:~  * Unstable angina~ * Uncontrolled hypertension~ * Myocardial infarction within the past 6 months (unless successfully treated with coronary artery bypass graft or percutaneous transluminal coronary angioplasty)~ * Uncontrolled arrhythmia~ * Congestive heart failure~ * At least 3 heart-related hospitalizations within the past year~* No severe chronic obstructive pulmonary disease requiring ≥ 3 hospitalizations within the past year~* No concurrent medical illness that would impair patient tolerance to therapy or limit survival~* No other invasive malignancy within the past 2 years~* No pre-existing peripheral sensory neuropathy ≥ grade 2~* No prior severe infusion reaction to a monoclonal antibody~* No prisoners or individuals who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior surgery~* Prior cisplatin and cetuximab allowed~* At least 6 months since prior radiotherapy or chemotherapy~* No prior radiotherapy \> 75 Gy~* No prior chemotherapy for recurrent head and neck cancer~  * Prior chemotherapy as a component of the primary treatment allowed~* No prior combination cisplatin, cetuximab, and radiotherapy for recurrent head and neck cancer~  * Patients with a new primary head and neck cancer whose prior primary head and neck cancer was treated with concurrent cisplatin, cetuximab, and radiotherapy are eligible provided it has been \> 6 months since treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm: Chemotherapy with Concurrent Radiation therapy (Type: EXPERIMENTAL): Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy intensity-modulated radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).